Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
28,000
Employees28,000
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
28,000
Employees28,000

AMGN Key Statistics

Market cap
149.90B
Market cap149.90B
Price-Earnings ratio
22.91
Price-Earnings ratio22.91
Dividend yield
3.35%
Dividend yield3.35%
Average volume
2.04M
Average volume2.04M
High today
$280.31
High today$280.31
Low today
$275.16
Low today$275.16
Open price
$280.00
Open price$280.00
Volume
2.15M
Volume2.15M
52 Week high
$339.17
52 Week high$339.17
52 Week low
$253.30
52 Week low$253.30

AMGN News

Simply Wall St 12h
Amgen And Kyowa Kirin Reveal Initial Results From Rocatinlimab ASCEND Study

and Kyowa Kirin Co., Ltd. announced promising preliminary results from their ASCEND study, focusing on a new therapy for atopic dermatitis, which could potentia...

Amgen And Kyowa Kirin Reveal Initial Results From Rocatinlimab ASCEND Study
Benzinga 1d
Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis

Amgen Inc. AMGN and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab in adults and adolescents with moderate to se...

Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis
TipRanks 2d
Amgen, Kyowa Kirin announce preliminary results from ASCEND study

Amgen (AMGN) and Kyowa Kirin announced preliminary top-line results from the ASCEND study evaluating rocatinlimab, an investigational T-cell rebalancing therapy...

Analyst ratings

48%

of 33 ratings
Buy
42.4%
Hold
48.5%
Sell
9.1%

More AMGN News

Simply Wall St 3d
A Look at Amgen’s Valuation Following FDA Nod Expanding Repatha’s Patient Reach

Amgen (AMGN) just received expanded FDA approval for its cholesterol-lowering drug, Repatha, allowing doctors to prescribe it to an even broader pool of adults...

A Look at Amgen’s Valuation Following FDA Nod Expanding Repatha’s Patient Reach
Yahoo Finance 6d
Biotech company Amgen set to build $600-million research center in Thousand Oaks - Yahoo Finance

...

Biotech company Amgen set to build $600-million research center in Thousand Oaks - Yahoo Finance
Benzinga 6d
Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug

On Wednesday, Amgen Inc. AMGN and its partner Zai Lab ZLAB said the final analysis of the Phase 3 FORTITUDE-101 trial evaluating bemarituzumab in combination wi...

Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug
TipRanks 7d
Sanofi’s ‘disappointing’ results to boost Regeneron shares, says Raymond James

Raymond James maintains an Outperform rating on Regeneron (REGN) shares and a Market Perform rating on Amgen (AMGN) after Sanofi (SNY) reported “disappointing”...

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.